Abstract
In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established. Interferon beta has also been shown to be efficacious in secondary-progressive multiple sclerosis (SPMS) as well as in patients with isolated syndromes at risk to develop clinically definite multiple sclerosis (MS). Mitoxantrone is another disease-modifying drug that is available for SPMS and severe cases of RRMS. The clinical utility of disease-modifying agents in MS will be reviewed with respect to the anti-inflammatory, immunomodulatory, and immunosuppressive treatments that are currently available. Symptomatic therapies will not be considered.
MeSH terms
-
Adjuvants, Immunologic / therapeutic use*
-
Analgesics / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Azathioprine / therapeutic use
-
Cyclophosphamide / therapeutic use
-
Cyclosporine / therapeutic use
-
Glatiramer Acetate
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunosuppressive Agents / therapeutic use*
-
Interferon-beta / therapeutic use
-
Methotrexate / therapeutic use
-
Mitoxantrone / therapeutic use
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / therapy
-
Multiple Sclerosis, Chronic Progressive / drug therapy
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy
-
Natalizumab
-
Peptides / therapeutic use
-
Plasma Exchange
Substances
-
Adjuvants, Immunologic
-
Analgesics
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Glucocorticoids
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents
-
Natalizumab
-
Peptides
-
Glatiramer Acetate
-
Interferon-beta
-
Cyclosporine
-
Cyclophosphamide
-
Mitoxantrone
-
Azathioprine
-
Methotrexate